Uveal Melanoma with Liver Metastases: Patient Experience, Treatment Challenges & Hope on the Hor

0 Views

07/09/23

This video describes key challenges associated with the treatment of uveal melanoma that has metastasized to the liver, provides insight into one person’s experience living with this disease, and offers information about the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial currently underway for adults with uveal melanoma with liver metastases.

The PERIO-01 trial, sponsored by TriSalus Life Sciences, is studying a new investigational drug, SD-101, delivered intravascularly by the TriNav® Infusion System using the Pressure-Enabled Drug Delivery™ (PEDD™) method of administration. The study is evaluating if this platform approach can improve the performance of systemic checkpoint inhibitors in treating uveal melanoma with liver metastases by overcoming two major challenges of treatment: immune response suppression and ineffective drug delivery. Additional information about the PERIO-01 trial can be found at www.PERIOtrial.com.

Dr. Richard D. Carvajal, MD, serves as associate professor of medicine, director of experimental therapeutics, and director of melanoma service at Columbia University’s Irving School of Medicine. He is also an investigator of the PERIO-01 clinical trial.

Karen Buerkle Kaludov, PhD, is a communications researcher and strategist based in Deale, MD. In 2021, Karen was diagnosed with uveal melanoma.